Bristol-Myers Squibb Co vs Mattel Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $129.94B), while Mattel Inc trades at $15.03 (market cap $4.30B). The key difference: Bristol-Myers Squibb Co is far larger — about 30.2× Mattel Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Mattel Inc pays none. Which is the better fit depends on your goals.
| BMY | MAT | |
|---|---|---|
Market Cap | $129.94B | $4.30B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $22.16 |
52-Week Low | $42.60 | $13.05 |
Enterprise Value | $163.92B | $6.52B |
Dividend Yield | 3.96% | — |
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →